BioStem Technologies, Inc., a regenerative medicine company specializing in perinatal tissue allograft products, reported financial results for the fourth quarter and full year ended December 31, 2025. The company faced significant revenue declines attributed to reimbursement uncertainty and competitive pressures in physician office and mobile settings, but maintained exceptionally high gross margins and completed a strategic acquisition aimed at diversifying its business.
For the fourth quarter of 2025, BioStem generated net revenue of $10.1 million, representing a 55% decrease compared to the same period in 2024. Despite the revenue decline, the company achieved a gross margin of 97%, up from 84% in Q4 2024, reflecting a product mix shift toward products without licensing fees. The company reported a GAAP net loss of $11.3 million for the quarter, compared to net income of $14.7 million in Q4 2024. Adjusted EBITDA was $3.4 million, down from $11.0 million in the prior year period.
Full year 2025 results showed net revenue of $47.5 million, down from $69.7 million in 2024. Gross profit for the year was $44.4 million, representing 94% of net revenue. The company reported a GAAP net loss of $6.6 million for 2025, compared to net income of $31.0 million in 2024. Operating expenses increased to $45.1 million from $24.8 million, driven by a charge for potentially uncollectible accounts receivable from Venture Medical, increased clinical trial activity, infrastructure investment, and costs associated with the BioTissue acquisition.
The company's strategic response to market challenges included the January 2026 acquisition of BioTissue Holdings Inc.'s surgical and wound assets. This acquisition significantly expands BioStem's product portfolio and commercial footprint while diversifying its end markets into the hospital setting. The integration includes approximately 20 direct sales representatives and managers, plus more than 30 independent sales agents from BioTissue. CEO Jason Matuszewski stated that with this acquisition, "BioStem is a fundamentally stronger and more diversified regenerative medicine company" with increased exposure to commercially insured patient populations.
BioStem provided financial guidance for 2026, anticipating first quarter revenue between $5 million and $6 million, with the hospital business expected to perform at historical levels of the acquired assets and the physician office business projected to decline significantly. The company expects to drive sequential and year-over-year growth in the hospital business during the second half of 2026 after completing integration activities and expanding its salesforce. As the physician office market stabilizes in the latter half of 2026, BioStem sees opportunity for sequential revenue growth improvement in that segment.
The company continues to pursue a Nasdaq uplisting, having appointed KPMG LLP as its independent registered public accounting firm in October 2025. BioStem expects to have audited financial statements for 2024 and 2025 in the near future, which represents a key prerequisite for the uplisting process. The company's quality management system and standard operating procedures have been accredited by the American Association of Tissue Banks and comply with current Good Tissue Practices and current Good Manufacturing Processes. More information about the company is available at https://biostemtechnologies.com.
This financial report highlights the significant challenges facing regenerative medicine companies in navigating evolving reimbursement landscapes while demonstrating how strategic acquisitions can provide diversification and potential pathways to recovery. The company's exceptionally high gross margins suggest strong underlying product economics, while the expansion into hospital markets through the BioTissue acquisition represents a calculated response to market pressures in physician office settings. The planned Nasdaq uplisting indicates BioStem's commitment to enhanced corporate governance and potentially broader investor access, though the company's near-term revenue projections suggest continued challenges before anticipated recovery in the latter half of 2026.
